Lifecore Biomedical earns FCPA declination for voluntary self-disclosure
By 
Kyle Brasseur2023-11-17T18:11:00
Pharmaceuticals company Lifecore Biomedical won’t face prosecution for apparent violations of the Foreign Corrupt Practices Act after satisfying multiple factors of the Department of Justice’s (DOJ) recently updated voluntary self-disclosure policy.
Lifecore’s legal representatives received a declination letter from the DOJ on Thursday, despite the agency finding evidence employees and agents of Lifecore’s former subsidiary Yucatan Foods engaged in bribes paid to Mexican government officials to secure a wastewater discharge permit.
Lifecore agreed to disgorge approximately $406,000 believed to be financial benefit attributable to the alleged bribery conduct.
Related articles
-
News BriefProterial Cable America earns DOJ declination in apparent fraud case
Proterial Cable America received a declination notice from the Department of Justice related to its voluntary self-disclosure and remediation of apparent fraud committed by its employees.
-
News BriefRaytheon parent discloses indications of improper payments in Middle East
RTX Corp., parent company of aerospace and defense giant Raytheon, disclosed an internal investigation launched into potential improper payments in connection with contracts in the Middle East found indications of misconduct.
-
PremiumDOJ cooperation credit breakdowns: Albemarle, Tysers, H.W. Wood
Nicole Argentieri, acting head of the Department of Justice’s Criminal Division, breaks down where Albemarle, Tysers Insurance Brokers, and H.W. Wood went right—and wrong—on the cooperation credit and remediation fronts as part of their FCPA settlements with the agency.
More from Regulatory Enforcement
-
News BriefFTC complaint accuses LA Fitness parent companies of blocking easy membership exits
The Federal Trade Commission filed a complaint against LA Fitness’ parent companies, citing difficulties canceling memberships, a month after a court blocked the agency’s click-to-cancel rule.
-
ArticleJudge orders CVS to pay nearly $290M for Medicare false claims
CVS’s Caremark division knowingly overcharged Medicare for prescription drugs and must pay nearly $290 million, a Pennsylvania federal judge has ordered.
-
News BriefSEC charges duo in $275 million water vending machine Ponzi scheme
The owner of a water machine vending company and a portfolio manager were allegedly behind a Ponzi-like scheme that raised more than $275 million, according to the U.S. Securities and Exchange Commission.